319: BioMarin's Executive Shakeup, A GLP-1 Lowers Diabetes Risk, And A Deep Look At Recursion's AI Bona Fides The Readout Loud podcast

Artwork

Drug Pricing Business Trends Business Stats

Inhoud geleverd door STAT. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door STAT of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

The Readout Loud « »
319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

28d ago 34:07

Delen

MP3•Thuis aflevering

Inhoud geleverd door STAT. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door STAT of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

It's a guest-free episode this week, giving Allison, Adam and Elaine ample time to chat about the management shakeup at BioMarin, including the announcement that James Sabry, the former Roche dealmaker, was joining the company as its new chief business officer. We can't seem to go a week without talking about GLP-1 medicines, so in true form, Elaine walks us through new study findings that showed Lilly's Zepbound greatly reduced the risk of diabetes. We also discuss a separate study that potentially links GLP-1 drugs to a higher rate of suicidal thoughts.

Lastly, Adam and Elaine interrogate Allison about her deeply reported corporate profile of AI drug developer Recursion. Is all the hype real?

… continue reading

325 afleveringen

#Drug Pricing #Business Trends #Business #Stats

Artwork

319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

The Readout Loud

232 subscribers

published 28d ago

Delen

MP3•Thuis aflevering

Inhoud geleverd door STAT. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door STAT of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

It's a guest-free episode this week, giving Allison, Adam and Elaine ample time to chat about the management shakeup at BioMarin, including the announcement that James Sabry, the former Roche dealmaker, was joining the company as its new chief business officer. We can't seem to go a week without talking about GLP-1 medicines, so in true form, Elaine walks us through new study findings that showed Lilly's Zepbound greatly reduced the risk of diabetes. We also discuss a separate study that potentially links GLP-1 drugs to a higher rate of suicidal thoughts.

Lastly, Adam and Elaine interrogate Allison about her deeply reported corporate profile of AI drug developer Recursion. Is all the hype real?

… continue reading

325 afleveringen

#Drug Pricing #Business Trends #Business #Stats

Tất cả các tập

×

Welkom op Player FM!

Player FM scant het web op podcasts van hoge kwaliteit waarvan u nu kunt genieten. Het is de beste podcast-app en werkt op Android, iPhone en internet. Aanmelden om abonnementen op verschillende apparaten te synchroniseren.

Luister naar 500+ onderwerpen